KCNQ5 polyclonal, anti-human, mouse, rat
€305.00
In stock
SKU
BS61680
Background:
Voltage-gated K+ channels in the plasma membrane control the repolarization and frequency of action potentials in neurons, muscles and other excitable cells. KCNQ proteins contain six transmembrane domains and function as tetramers. KCNQ4 forms heteromeric channels with KCNQ3 and is expressed in several tissues, including the cochlea, where it is present in outer hair cells. KCNQ5 expression is highest in the brain and muscle. Out of the three splice variants of KCNQ5, the longest variant, KCNQ5 type III, is the predominant form expressed in skeletal muscle. The gene encoding human KCNQ5 maps to chromosome 6q13. Mutations in the gene encoding KCNQ2, but not in the gene encoding KCNQ5, lead to benign familial neonatal convulsions, while mutations in the genes encoding for KCNQ1 and KCNE1 lead to cardiac disease because they directly impair electrical signaling. Mutations in KCNQ4 are implicated in the onset of deafness.
Alternative Name:
Potassium voltage-gated channel subfamily KQT member 5, KQT-like 5, Potassium channel subunit alpha KvLQT5, Voltage-gated potassium channel subunit Kv7.5, KCNQ5
Application Dilution: WB: 1:500~1:1000
Specificity: KCNQ5 polyclonal antibody detects endogenous levels of KCNQ5 protein.
Immunogen:
Synthetic peptide, corresponding Human KCNQ5.
MW: ~ 102 kDa
Swis Prot.: Q9NR82
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.3.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
Voltage-gated K+ channels in the plasma membrane control the repolarization and frequency of action potentials in neurons, muscles and other excitable cells. KCNQ proteins contain six transmembrane domains and function as tetramers. KCNQ4 forms heteromeric channels with KCNQ3 and is expressed in several tissues, including the cochlea, where it is present in outer hair cells. KCNQ5 expression is highest in the brain and muscle. Out of the three splice variants of KCNQ5, the longest variant, KCNQ5 type III, is the predominant form expressed in skeletal muscle. The gene encoding human KCNQ5 maps to chromosome 6q13. Mutations in the gene encoding KCNQ2, but not in the gene encoding KCNQ5, lead to benign familial neonatal convulsions, while mutations in the genes encoding for KCNQ1 and KCNE1 lead to cardiac disease because they directly impair electrical signaling. Mutations in KCNQ4 are implicated in the onset of deafness.
Alternative Name:
Potassium voltage-gated channel subfamily KQT member 5, KQT-like 5, Potassium channel subunit alpha KvLQT5, Voltage-gated potassium channel subunit Kv7.5, KCNQ5
Application Dilution: WB: 1:500~1:1000
Specificity: KCNQ5 polyclonal antibody detects endogenous levels of KCNQ5 protein.
Immunogen:
Synthetic peptide, corresponding Human KCNQ5.
MW: ~ 102 kDa
Swis Prot.: Q9NR82
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.3.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review